NR3C2 and Hyperglycemia: SGLT2i primarily inhibit glucose reabsorption in the proximal tubule, thereby reducing hyperglycemia and intraglomerular pressure, while finerenone blocks mineralocorticoid receptor overactivation, mitigating inflammation, fibrosis, and oxidative stress in podocytes and tubular cells [9].